Related Experiment Video
Updated: Dec 23, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer
Anthony V Serritella1, Christine M Bestvina2
1Department of Medicine, University of Chicago Medicine, 5841 South Maryland Avenue, MC 3051, Chicago, IL 60637, USA.
Abstract:
The treatment of patients with advanced non-small cell lung cancer with anaplastic lymphoma kinase chromosomal rearrangements has been revolutionized by the development of tyrosine kinase inhibitors (TKIs). Excellent progress has been made over the past decade, with 4 TKIs now approved in the front-line setting. Alectinib is the preferred first-line option based on its efficacy and side-effect profile. The central nervous system (CNS) activity of alectinib and brigatinib has allowed for treatment of CNS metastases with TKI therapy. Once resistance inevitably develops, newer therapies such as lorlatinib can be considered.
Insights
Tyrosine kinase inhibitors (TKIs) have transformed advanced non-small cell lung cancer treatment, especially for anaplastic lymphoma kinase rearrangements. Alectinib is a preferred first-line TKI, with newer options like lorlatinib available upon resistance.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Advanced non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) rearrangements presents a significant therapeutic challenge.
- The advent of tyrosine kinase inhibitors (TKIs) has dramatically altered the treatment landscape for ALK-positive NSCLC.
- Several TKIs are now approved for first-line treatment, offering improved outcomes for patients.
Purpose of the Study:
- To review the advancements in TKI therapy for ALK-positive NSCLC.
- To highlight the efficacy and tolerability of current first-line TKIs, particularly alectinib.
- To discuss the management of central nervous system (CNS) metastases and acquired resistance to TKIs.
Main Methods:
- Review of clinical trial data and published literature on TKIs in NSCLC.
- Comparative analysis of efficacy, safety, and CNS penetration of various ALK inhibitors.
- Discussion of resistance mechanisms and subsequent treatment strategies.
Main Results:
- Four TKIs are now approved for first-line treatment of ALK-positive NSCLC, with alectinib demonstrating superior efficacy and a favorable side-effect profile.
- Alectinib and brigatinib exhibit significant central nervous system (CNS) activity, enabling effective treatment of brain metastases.
- Acquired resistance to existing TKIs is a clinical reality, necessitating the development of next-generation agents.
Conclusions:
- Alectinib is the preferred first-line TKI for advanced ALK-positive NSCLC due to its robust efficacy and tolerability.
- TKIs targeting ALK, such as alectinib and brigatinib, provide crucial treatment options for patients with CNS metastases.
- Lorlatinib represents a valuable therapeutic option for patients who develop resistance to earlier-generation TKIs, underscoring the evolving treatment paradigm.
